Login
Scinai Immunotherapeutics Ltd logo

Scinai Immunotherapeutics Ltd

scinai.com

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Financial Snapshot

Revenue
TTM
$2.779M
Gross Margin
TTM
-169.07%
Net Income
TTM
-$11.09M
Current Assets
2026 Q1
$3.614M
Current Liabilities
2026 Q1
$2.685M
Current Ratio
2026 Q1
134.6%
Total Assets
2026 Q1
$17.59M
Total Liabilities
2026 Q1
$5.827M
Book Value
2026 Q1
11.76M
Cash
2026 Q1
$2.963M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$8.590M

Stock Price

Loading...
Market Cap: $1.081 Million

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support